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ABSTRACT 
 
The goal of this study was to describe the longterm outcome of patients with tuberculosis 
(TB) complicating TNF-α blocker therapy.  All cases of tuberculosis (21) complicating TNF-
α blocker therapy from French University Hospitals were collated between January 2000 and 
Saptember 2002.  Patient outcome was assessed via a postal questionnaire in September 2005. 
After 4 years of follow-up, the mortality rate was 4.8%, 1 patient had relapsed and 6 patients 
(29%) had restarted TNF-α antagonist treatment after appropriate antituberculous therapy, 
without reactivation.  
Our data support the concept that TNFα antagonists can be restarted in patients diagnosed 
with TB provided adequate antituberculous treatment has been completed. 
 
 
Tumor Necrosis Factor α (TNF-α) induces intracellular death of Mycobacterium tuberculosis, 
macrophage apoptosis and granuloma formation [1-3]. Keane et al. [4] were the first to 
describe an increased incidence of TB in  patients with rheumatoid arthritis (RA) treated with 
TNF-α blockers. The relative risk of developing TB whilst on this therapy in this patient 
group has been estimated in the USA and Europe at ≥4 [4-7]. In France, a national 
multidisciplinary group called RATIO (Research Axed on Tolerance of bIOtherapies) was set 
up to further the knowledge, prevention and care of opportunistic infections associated with 
TNF-α antagonists. We report here the long-term outcome of 21 patients in France who 
developed TB whilst on TNF-α blockers.  All cases of TB in patients treated with TNF-α 
blockers between 1st January 2000 (first TNF-α antagonist use in France) and 30th September 
2002 were collected from the gastroenterology, rheumatology, infectious diseases and internal 
medicine units of all French University hospitals. A Clinical Research Assistant then collected  
all the available data for each TB case. On-site visits took place from 15th October 2002 to 
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22st January 2003.  Postal questionnaires regarding the patients’ outcomes were sent in 
September 2005 and information collected up to January 2006. 
Overall, 25 definite or probable TB cases were reported. 21 cases from 19 different 
centers were retained for analysis (2 cases could not be validated by an on-site visit, the same 
patient was declared twice in one case and the diagnosis of TB was not retracted in the last 
case).  
The underlying inflammatory disease, patients’ demographic characteristics and 
concomitant immunosuppressive treatments are shown in Table 1. Most patients had RA and 
they were all receiving infliximab. Seventeen patients were also treated with corticosteroids at 
diagnosis with a median daily dosage of prednisolone of 10 mg [range 4-65mg]. Additional 
immunosuppressive factors included chronic hepatitis C in 1 case and neoplasia in 4 cases: 1 
thyroid carcinoma diagnosed after starting infliximab and treated surgically, 1 endometrial 
carcinoma treated and cured 7 years before starting TNFα blocker therapy, 1 breast carcinoma  
treated 11 years before starting TNFα blockers and 1 chronic lymphoid leukaemia (CLL) 
diagnosed one month after the initiation  of TNFα blocker therapy. These patients received 
TNFα blockers because they had very severe forms of RA.  
Nine patients (43%) reported at least one of the following previous events: contact 
with a patient with TB or primary infection or microbiologically confirmed TB treated with  
antituberculous treatment (Table 2). Fever was the initial symptom in 16 patients. The mean 
duration between first symptoms and the diagnosis of TB was 38 days [range 3-153 days].  In 
8 patients (38%), lung was the only organ involved (5 with a prolonged cough). Four patients 
(19%) had only extra-pulmonary involvement consisting of lymphadenitis in all cases. In 
eight patients (38%), the lung and at least one other system were involved  - lymphadenitis in 
3 cases, peritonitis in 1 case, urinary tract infection  in 1 case, bone (elbow) involvement in 1 
case, spleen  in 1 case and the combination of lymphadenitis, spleen and hepatic involvement 
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in the remaining case. One patient had no precise clinical localization. As previously observed 
[4], the frequency of extra-pulmonary and  disseminated forms were  particularly high in these 
patients treated with TNF-α blockers (57% of patients). The direct staining examination of the 
specimen was positive for acid-fast bacilli in 6 out of 21 patients and the culture was positive 
for M. tuberculosis for 19 patients. For the two patients with negative culture, one diagnosis 
was obtained by positive specific M. tuberculosis complex PCR in the bronchoalveolar lavage 
fluid and the other by a positive Mantoux’s test (from 6 to 20 mm) with compatible clinical 
symptoms and a good response to antituberculous treatment.  
Patients received antituberculous therapy for 8.5 months range 1-14 months]: 7 started 
with triple therapy (6 with isoniazid, rifampin, ethambutol, 1 with isoniazid, rifampin, 
ofloxacin), 13 (61.9%) with quadruple therapy (isoniazid, rifampin, ethambutol, 
pyrazinamide) and 1 died before initiation of antituberculous treatment.   
A TB relapse was observed in 1 patient in 2004 (microbiologically-confirmed lymph 
node localization); initial antituberculous treatment had been taken for 6 months and the 
isolate remained susceptible to all four drugs taken. The patient was retreated for 9 months 
and cured but he did not resume TNF-α blocker therapy. 
The most recent information concerning the health status of patients was obtained via 
a postal questionnaire sent approximately 4 years after the commencement of antituberculous 
treatment. At this time, 15 patients were alive and all of them were cured. Among the 6 cases 
who died, death was formally attributed to TB in 1 patient (4.8%). Five deaths were not 
related to TB: cardiac failure in 2 cases, acute respiratory failure in 2 cases and a 
cerebrovascular accident in 1 case. Patients received the following treatments: corticosteroids 
in 4 patients, methotrexate in 4 patients, leflunomide in 4 patients, salazopyrine in 1 patient, 
thalidomide in 1 patient, polyvalent immunoglobulins in 1 patient, infliximab in 3 patients, 
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etanercept in 2 patients (initially 3 patients but 1 switched afterwards for infliximab) and 
adalimumab in 1 patient.  
Six patients restarted TNF-α blockers: 12 months after the initiation of anti 
tuberculous treatment for 3 patients and 2, 3, and 7.5 months after for the 3 others 
respectively. Treatment consisted of infliximab for 2 patients, etanercept for 3 patients and 
adalimumab for 1 patient. One in the etanercept group was later switched to  infliximab. None 
of the 6 patients restarted on TNF-α antagonist treatment developed a reactivation of TB or 
developed another opportunistic infection and their subjective quality of life improved. The 
mean follow-up for these 6 patients since commencing antituberculous treatment was 42.7 
months (18-60).  
The guidelines of the British Society of Rheumatology [8, 9] recommend continuation of 
TNF-α blockers (with  treatment of TB) for patients who develop active TB while on TNF-α 
blockers, if the expected benefit for  the inflammatory disease is strong. To our knowledge, 
this is the first description of the long-term surveillance of patients having developed TB 
whilst treated with TNF-α blocker therapy who are then  safely resumed on TNF treatment 
once successfully treated with  appropriate antituberculous therapy. 
Our data strongly suggest that TB is not a contraindication to restarting anti-TNF-α therapy if 
the underlying inflammatory disease requires it. 
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Table 1. Underlying conditions and immunosuppressive therapy in 21 patients treated 
with TNF-α blockers who developed tuberculosis in France 
  
Rheumatoid 
arthritis 
 
 
(N = 14, 66.7%) 
 
Ankylosing 
spondylitis 
 
 
(N = 2, 9.5%) 
 
Crohn’s 
disease 
 
 
(N = 2, 9.5%) 
 
Other diseases: 
Polymyositis  
Psoriatic arthritis 
 
(N = 3, 14.3%) 
 
Total 
 
 
 
(N = 21) 
 
% 
 
Male / Female 
 
6 / 8 
 
1 / 1 
 
1 / 1 
 
1 / 2 
 
9 / 12 
 
Median age (range) at 
the 1st symptom (yrs) 
 
65 (45-85) 
 
50 (46-54) 
 
34 (28-40) 
 
67 (53-63)   
Mean (± SD) duration 
of disease (yrs) 
10.1 ± 5.0  
 
32.2 ± 2.7 
 
12.4 ± 4.1 
 
12.6 ± 6.6   
 
Type of treatment at 
diagnosis of 
tuberculosis: 
   I 
   I + azathioprine 
   I + cyclosporine 
   I + leflunomide 
   I + leflunomide +      
hydroxychloroquine 
   I + methotrexate 
   I + purinethol 
   Corticosteroids* 
 
 
Infliximab treatment : 
-Mean (± SD) 
infliximab dosage 
(mg/kg) 
 
-Mean (± SD) number 
of infliximab perfusions 
at first symptoms 
 
 
-Mean (± SD) duration 
of treatment with 
infliximab (weeks) 
 
 
Mean (± SD) duration 
of immunosuppression 
(years) 
 
 
 
 
1 
0 
1 
2 
1 
 
9 
0 
12 
 
 
 
3.3±0.5 
 
 
 
3.5±1.9 
 
 
 
 
13±12.5 
 
 
 
 
8.1±4.5 
 
 
 
 
0 
0 
0 
0 
0 
 
2 
0 
1 
 
 
 
3.0±0.0 
 
 
 
3.0±0.0 
 
 
 
 
12±3.1 
 
 
 
 
7.6±12.8 
 
 
 
 
0 
1 
0 
0 
0 
 
0 
1 
1 
 
 
 
5.1±0.2 
 
 
 
3.0±0.0 
 
 
 
 
26.5±13 
 
 
 
 
6.6±2.5 
 
 
 
 
2 
0 
0 
0 
0 
 
1 
0 
3 
 
 
 
6.5±3.0 
 
 
 
3.0±1.0 
 
 
 
 
9.4±3.6 
 
 
 
 
7.4±9.2 
 
 
 
 
3 
1 
1 
2 
1 
 
12 
1 
17 
 
 
 
3.9±1.7 
 
 
 
3.3±1.6 
 
 
 
 
13.5± 
11.4 
 
 
 
7.8±6.0 
 
 
 
 
14.3 
4.8 
4.8 
9.5 
4.8 
 
57.1 
4.8 
81 
 
 
 
- 
 
 
 
- 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
 
I: infliximab; *corticosteroids were combined to immunosuppressive therapy 
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Table 2. Past medical history in 21 patients with tuberculosis occurring during 
treatment with TNF-α blockers 
 
 Present * 
 
Absent Undetermined 
Vaccination (BCG) 5 (24%) 7 (33%) ** 9 (43%) 
Previous exposure to M. 
tuberculosis 
6 (29%) 13 (62%) 2 (10%) 
Past history of  tuberculosis 
primary infection 
7 (33%) 12 (57%) 2 (10%) 
Treatment of tuberculosis 
primary infection (TPI) 
2 (29%) 2 (29%) 3 (42%) 
Past history of tuberculosis 
disease 
1 (5%) 19 (90%) 1 (5%) 
 
* All of them had received vaccination at least 10 years before diagnosis  
** 3 foreigners, others born in France in 1920, 1942 (past history of TPI), 1946 (past history 
of TPI), 1955 (past history of TPI) 
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